Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Capital Expenditures (2018 - 2019)

Endonovo Therapeutics has reported Capital Expenditures over the past 2 years, most recently at $723.0 for Q3 2019.

  • Quarterly results put Capital Expenditures at $723.0 for Q3 2019, changed N/A from a year ago — trailing twelve months through Dec 2019 was $723.0 (down 91.94% YoY), and the annual figure for FY2019 was $2594.0, down 71.08%.
  • Capital Expenditures for Q3 2019 was $723.0 at Endonovo Therapeutics, down from $8969.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for ENDV hit a ceiling of $8969.0 in Q1 2018 and a floor of $723.0 in Q3 2019.